ABSTRACT
A safe and effective medical waste transport network is beneficial to control the COVID-19 pandemic and at least decelerate the spread of novel coronavirus. Seldom studies concentrated on a two-phase COVID-19 medical waste transport in the presence of multi-type vehicle selection, sustainability, and infection probability, which is the focus of this paper. This paper aims to identify the priority of sustainable objectives and observe the impacts of multi-phase and infection probability on the results. Thus, such a problem is formulated as a mixed-integer programming model to minimise total potential infection risks, minimise total environmental risks, and maximise total economic benefits. Then, a hybrid solution strategy is designed, incorporating a lexicographic optimisation approach and a linear weighted sum method. A real-world case study from Chongqing is used to illustrate this methodology. Results indicate that the solution strategy guides a good COVID-19 medical waste transport scheme within 1 min. The priority of sustainable objectives is society, economy, and environment in the first and second phases because the total Gap of case No.35 is 3.20%. A decentralised decision mode is preferred to design a COVID-19 medical waste transport network at the province level. Whatever the infection probability is, infection risk is the most critical concern in the COVID-19 medical waste clean-up activities. Environmental and economic sustainability performance also should be considered when infection probability is more than a certain threshold.
ABSTRACT
Colchicine is an ancient herbal drug derived from Colchicum autumnale. It was first used to treat familial Mediterranean fever and gout. Based on its unique efficacy as an anti-inflammatory agent, colchicine has been used in the therapy of cardiovascular diseases including coronary artery disease, atherosclerosis, recurrent pericarditis, vascular restenosis, heart failure, and myocardial infarction. More recently, colchicine has also shown therapeutic efficacy in alleviating cardiovascular complications of COVID-19. COLCOT and LoDoCo2 are two milestone clinical trials that confirm the curative effect of long-term administration of colchicine in reducing the incidence of cardiovascular events in patients with coronary artery disease. There is growing interest in studying the anti-inflammatory mechanisms of colchicine. The anti-inflammatory action of colchicine is mediated mainly through inhibiting the assembly of microtubules. At the cellular level, colchicine inhibits the following: (1) endothelial cell dysfunction and inflammation; (2) smooth muscle cell proliferation and migration; (3) macrophage chemotaxis, migration, and adhesion; (4) platelet activation. At the molecular level, colchicine reduces proinflammatory cytokine release and inhibits NF-κB signaling and NLRP3 inflammasome activation. In this review, we summarize the current clinical trials with proven curative effect of colchicine in treating cardiovascular diseases. We also systematically discuss the mechanisms of colchicine action in cardiovascular therapeutics. Altogether, colchicine, a bioactive constituent from an ancient medicinal herb, exerts unique anti-inflammatory effects and prominent cardiovascular actions, and will charter a new page in cardiovascular medicine.